The effects of sitagliptin on gastric emptying in healthy humans - A randomised, controlled study

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 4, 2012, Pages 379-390

  Stevens, J E ^a,b   Horowitz, M ^a   Deacon, C F ^c   Nauck, M ^d   Rayner, C K ^a   Jones, K L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Nutritional Physiology Interventions and Outcomes   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PLACEBO; SITAGLIPTIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; STOMACH EMPTYING;

BLOOD GLUCOSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INTESTINAL ABSORPTION; MALE; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES; YOUNG ADULT;

EID: 84863988113     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05198.x     Document Type: Article

References (60)

1. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW,. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-62.
2. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, et al,. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 3829-34.
3. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L,. Gastric emptying in "early" noninsulin-dependent diabetes mellitus. J Nucl Med 1996; 37: 1643-8.
4. Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL, Horowitz M, et al,. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med 2012; 29: 604-8.
5. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, et al,. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3431-5.
6. Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K,. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994; 17: 901-3.
7. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, et al,. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007; 293: E743-53.
8. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W,. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-7.
9. Nauck MA, Holst JJ, Willms B,. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 1997; 29: 411-6.
10. Ritzel R, Orskov C, Holst JJ, Nauck MA,. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-5.
11. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A,. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-92.
12. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al,. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91: 1916-23.
13. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, et al,. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277: R910-6.
14. Schirra J, Houck P, Wank U, Arnold R, Goke B, Katschinski M,. Effects of glucagon- like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000; 46: 622-31.
15. Brennan IM, Feltrin KL, Horowitz M, Smout AJ, Meyer JH, Wishart J, et al,. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1477-85.
16. Flint A, Raben A, Astrup A, Holst JJ,. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-20.
17. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al,. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-9.
18. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al,. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2719-25.
19. Meier JJ, Kemmeries G, Holst JJ, Nauck MA,. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005; 54: 2212-8.
20. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, et al,. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95: 215-21.
21. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al,. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55: 243-51.
22. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al,. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48: 86-93.
23. Nicolaus M, Brodl J, Linke R, Woerle HJ, Goke B, Schirra J,. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011; 96: 229-36.
24. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA,. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 2010; 59: 1330-7.
25. Witte AB, Gryback P, Jacobsson H, Naslund E, Hellstrom PM, Holst JJ, et al,. Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. Scand J Gastroenterol 2011; 46: 428-35.
26. Nauck MA, Baller B, Meier JJ,. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53 (Suppl. 3): S190-6.
27. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W,. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
28. Deacon CF,. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2007; 9 (Suppl. 1): 23-31.
29. Verspohl EJ,. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009; 124: 113-38.
30. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ,. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172: 355-62.
31. Drucker DJ,. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12: 87-100.
32. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, et al,. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo- controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
33. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al,. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo- controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-88.
34. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al,. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-9.
35. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al,. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-94.
36. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, et al,. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007; 56: 1475-80.
37. Woerle HJ, Lindenberger T, Linke R, Foley JE, Ligueros-Saylan AA, Zhang Y, et al,. A single dose of vildagliptin (VILDA) decelerates gastric emptying (GE) in patients with type 2 diabetes (T2DM). American Diabetes Association, 67th Scientific Sessions 2007; 500-P (abstract): A133.
38. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, et al,. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide- induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007; 92: 4165-71.
39. Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C,. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin- dependent diabetes mellitus. Gastroenterology 1997; 113: 60-6.
40. Rayner CK, Ma J, Pilichiewicz AN, Feinle-Bisset C, Checklin H, Jones KL, et al,. Effects of variations in duodenal glucose load on glycaemia, insulin and GLP-1 in type 2 diabetes. Diabetologia 2009; 52 (Suppl. 1): S105-6.
41. Collins PJ, Horowitz M, Cook DJ, Harding PE, Shearman DJ,. Gastric emptying in normal subjects-a reproducible technique using a single scintillation camera and computer system. Gut 1983; 24: 1117-25.
42. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ,. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18: 229-34.
43. Holst JJ,. Enteroglucagon. Annu Rev Physiol 1997; 59: 257-71.
44. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ,. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-9.
45. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al,. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-13.
46. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ,. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-81.
47. Gentilcore D, Chaikomin R, Jones KL, Russo A, Feinle-Bisset C, Wishart JM, et al,. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2062-7.
48. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al,. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-50.
49. Nauck MA, Kemmeries G, Holst JJ, Meier JJ,. Rapid tachyphylaxis of the glucagon- like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-5.
50. Jones KL, Kong MF, Berry MK, Rayner CK, Adamson U, Horowitz M,. The effect of erythromycin on gastric emptying is modified by physiological changes in the blood glucose concentration. Am J Gastroenterol 1999; 94: 2074-9.
51. Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, et al,. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011; 152: 3018-29.
52. Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, et al,. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004; 286: E621-5.
53. Edholm T, Degerblad M, Gryback P, Hilsted L, Holst JJ, Jacobsson H, et al,. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 2010; 22: 1191-200.
54. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR,. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166-70.
55. Witte AB, Gryback P, Holst JJ, Hilsted L, Hellstrom PM, Jacobsson H, et al,. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009; 158: 57-62.
56. Wishart JM, Horowitz M, Morris HA, Jones KL, Nauck MA,. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 1998; 19: 1049-53.
57. O'Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilcore D, et al,. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 2004; 47: 2208-14.
58. Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, et al,. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010; 73: 189-96.
59. Vardarli I, Nauck MA, Kothe LD, Deacon CF, Holst JJ, Schweizer A, et al,. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with Type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 945-54.
60. Hansen L, Hartmann B, Mineo H, Holst JJ,. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 2004; 118: 11-8.